Trial Information

Summary: A Phase II Study of Oral LBH589 in Adult Patients with Refractory Cutaneous T-Cell Lymphoma

You have been asked to participate in this research study because you have a type of cancer that involves the skin called cutaneous T-cell lymphoma, either Mycosis fungoides or Sézary syndrome, that is no longer responding to the treatments you have already been given.  The purpose of this study is to evaluate the safety and anti-cancer effects of the investigational drug LBH589.  In addition, the study will look at the internal workings of a cancer cell to find out how LBH589 affects the abnormal way cancer cells grow.  Your participation in this study is expected to last at least four weeks (one cycle of treatment).  If you are tolerating treatment and your medical condition is not getting worse, you will be able to receive additional cycles of treatment.  After you discontinue treatment, your medical condition will continue to be followed indefinitely.

Patient Inclusion/Exclusion Criteria:

- See http://clinicaltrials.coh.org for additional information.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: July 7, 2008 at 2:41:24 PM